RESUMO
5-(Trifluoroacetyl)thiophene-2-carboxamides were found to be potent and selective class II HDAC inhibitors. This paper describes their further development and the investigation on the cause for the lack of cell-based activity. A rapid screening assay was set up which enabled the identification of more metabolic stable compounds as potent and selective class II HDAC inhibitors.
Assuntos
Amidas/síntese química , Amidas/farmacologia , Inibidores de Histona Desacetilases , Tiofenos/síntese química , Tiofenos/farmacologia , Amidas/química , Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Citocromo P-450 CYP2C9 , Desenho de Fármacos , Células HCT116 , Células HeLa , Hepatócitos/efeitos dos fármacos , Histona Desacetilases/classificação , Humanos , Microssomos Hepáticos/efeitos dos fármacos , Estrutura Molecular , Relação Estrutura-Atividade , Tiofenos/química , Tubulina (Proteína)/efeitos dos fármacosRESUMO
The application of a phosphoramidate prodrug approach to 2'-C-methylcytidine (NM107), the first nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, is reported. 2'-C-Methylcytidine, as its valyl ester prodrug (NM283), was efficacious in reducing the viral load in patients infected with HCV. Several of the phosphoramidates prepared demonstrated a 10- to 200-fold superior potency with respect to the parent nucleoside in the cell-based replicon assay. This is due to higher levels of 2'-C-methylcytidine triphosphate in the cells. These prodrugs are efficiently activated and converted to the triphosphate in hepatocytes of several species. Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides.
Assuntos
Amidas/metabolismo , Amidas/uso terapêutico , Antivirais/metabolismo , Citidina/análogos & derivados , Hepatite C/tratamento farmacológico , Ácidos Fosfóricos/metabolismo , Ácidos Fosfóricos/uso terapêutico , Pró-Fármacos/metabolismo , Pró-Fármacos/uso terapêutico , Amidas/farmacologia , Amidas/toxicidade , Animais , Antivirais/farmacologia , Antivirais/uso terapêutico , Antivirais/toxicidade , Linhagem Celular , Citidina/metabolismo , Citidina/farmacologia , Citidina/uso terapêutico , Citidina/toxicidade , Hepacivirus/efeitos dos fármacos , Hepacivirus/fisiologia , Hepatócitos/efeitos dos fármacos , Hepatócitos/metabolismo , Hepatócitos/virologia , Humanos , Ácidos Fosfóricos/farmacologia , Ácidos Fosfóricos/toxicidade , Polifosfatos/metabolismo , Pró-Fármacos/farmacologia , Pró-Fármacos/toxicidade , Relação Estrutura-Atividade , Replicação Viral/efeitos dos fármacosRESUMO
A rapid and sensitive radiometric assay for assessing the potential of drugs to inhibit cytochrome P450 (P450) 2C9 in human liver microsomes is described. In contrast to the conventional diclofenac 4'-hydroxylation assay, the new method does not require high performance liquid chromatography (HPLC) separation and mass spectrometry. The assay is based on the release of tritium as tritiated water that occurs upon CYP2C9-mediated 4'-hydroxylation of diclofenac labeled with tritium in the 4' position. The radiolabeled product is separated from the substrate using 96-well solid-phase extraction plates. The reaction is NADPH-dependent, and sensitive to CYP2C9 inhibitors and inhibitory monoclonal antibodies, but not to inhibitors of or antibodies against other P450 enzymes. Competition experiments using tritiated and unlabeled diclofenac indicated that CYP2C9-mediated diclofenac 4'-hydroxylation exhibits positive cooperativity and no significant kinetic isotope effect or NIH shift. IC(50) values for 18 structurally diverse chemical inhibitors were not significantly different from those determined in the diclofenac 4'-hydroxylation assay, using HPLC-tandem mass spectrometry. All the steps of the new assay, namely, incubation, product separation, and radioactivity counting, are performed in 96-well format and can be automated. This assay thus represents a high-throughput version of the classic diclofenac 4'-hydroxylation assay, which is one of the most widely used methods to assess the potential for CYP2C9 inhibition of new chemical entities.
Assuntos
Hidrocarboneto de Aril Hidroxilases/antagonistas & inibidores , Inibidores Enzimáticos/análise , Radiometria/métodos , Anticorpos Monoclonais/análise , Anticorpos Monoclonais/farmacologia , Hidrocarboneto de Aril Hidroxilases/metabolismo , Automação , Citocromo P-450 CYP2C9 , Diclofenaco/análogos & derivados , Diclofenaco/análise , Diclofenaco/metabolismo , Inibidores Enzimáticos/farmacologia , Humanos , Hidroxilação , Microssomos Hepáticos/metabolismo , Reprodutibilidade dos Testes , Teofilina/análogos & derivados , Teofilina/farmacologia , Trítio/análise , ÁguaRESUMO
A rapid and sensitive radiometric assay for assessing the potential of drugs to inhibit cytochrome P450 (P450) 3A4/5 in human liver microsomes is described. In contrast to the conventional testosterone 6beta-hydroxylation assay, the new method does not require high-performance liquid chromatography (HPLC) separation and mass spectrometry. The assay is based on the release of tritium as tritiated water that occurs upon CYP3A4/5-mediated 6beta-hydroxylation of testosterone labeled with tritium in the 6beta position. The radiolabeled product is separated from the substrate using 96-well solid-phase extraction plates. Using commercially available [1,2,6,7-(3)H]testosterone as substrate, we demonstrated that the reaction is NADPH-dependent, and sensitive to CYP3A4/5/5 inhibitors and a CYP3A4/5/5-specific inhibitory monoclonal antibody, but not to inhibitors of or antibodies against other P450 enzymes. The method was further improved by synthesis of testosterone specifically tritiated in the 6beta position, which displayed greatly improved conversion rate with an ensuing increase in assay sensitivity. Competition experiments using tritiated and unlabeled testosterone indicated that CYP3A4/5-mediated 6beta-hydroxylation exhibits positive cooperativity and a modest kinetic isotope effect. IC(50) values for more than 40 structurally diverse chemical inhibitors were not significantly different from those determined in the testosterone 6beta-hydroxylation assay, using HPLC-tandem mass spectrometry analysis. All the steps of the new assay, namely, incubation, product separation, and radioactivity counting, are performed in 96-well format and can be automated. This assay thus represents a high-throughput version of the classical testosterone 6beta-hydroxylation assay, which is the most widely used method to assess the potential for CYP3A4/5 inhibition of new chemical entities.